The influence of carrier and drug morphology on drug delivery from dry powder formulations.

Lactose was crystallised either from neutralised Carbopol 934 gel or from water-ethanol solution without stirring, with a view to obtaining lactose alpha-monohydrate of favourable shape and smooth surface, suitable for use as carriers in formulations for dry powder inhalers (DPIs). Crystallisation of salbutamol sulphate was carried out in the presence of water, lecithin and ethanol to form salbutamol crystals with defined shape and smooth surface. The crystals formed were needle-shaped, with a length of less than 6 microm and a width between 0.5 and 1 microm. DSC and TGA showed that lactose crystals produced from Carbopol gel or from water-ethanol solution existed as alpha-lactose monohydrate. The DSC thermograms of micronised and crystallised salbutamol sulphate showed two similar endothermic transitions at 200 and 290 degrees C, respectively. The first transition was initially thought to correspond to the melting of salbutamol sulphate. However, the shape of the particles as observed by optical microscopy was not altered after heating the sample to 250 degrees C, suggesting that no transition from solid to liquid state occurred at 200 degrees C. This was confirmed by observations made using hot stage microscopy. The two endothermic transitions are suggested to correspond to the decomposition of the salbutamol sulphate molecule. The elongation ratio of the commercial lactose crystals, lactose crystallised from Carbopol and from water-ethanol were 1.69+/-0.05, 2.01+/-0.13 and 6.25+/-0.17, respectively. As the elongation ratio increased the flow properties of the carrier were affected detrimentally and this consequently reduced the content uniformity of salbutamol sulphate and drug emission from the inhaler device. Whereas, increasing the elongation ratio of the carrier or drug improved the deposition profiles of salbutamol sulphate, suggesting that the more elongated particles would be more aerodynamic and favour deep lung penetration.

[1]  I Gonda,et al.  Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract. , 1990, Critical reviews in therapeutic drug carrier systems.

[2]  G P Martin,et al.  The influence of carrier morphology on drug delivery by dry powder inhalers. , 2000, International journal of pharmaceutics.

[3]  C. Washington.  Particle size analysis in pharmaceutics and other industries : theory and practice , 1992 .

[4]  S. Clarke,et al.  Therapeutic aerosols 1--physical and practical considerations. , 1983, Thorax.

[5]  P. Lucas,et al.  Protein Deposition from Dry Powder Inhalers: Fine Particle Multiplets as Performance Modifiers , 1998, Pharmaceutical Research.

[6]  Amin A. Elamin,et al.  The use of amorphous model substances to study mechanically activated materials in the solid state , 1995 .

[7]  A. Michaels,et al.  THE EFFECT OF SURFACE ACTIVE AGENTS ON CRYSTAL GROWTH RATE AND CRYSTAL HABIT , 1960 .

[8]  G. Hanlon,et al.  An investigation into the deposition of inhalation aerosol particles as a function of air flow rate in a modified ‘Kirk Lung’ † , 1976, The Journal of pharmacy and pharmacology.

[9]  G. P. Martin,et al.  Crystallization of Lactose from Carbopol Gels , 2000, Pharmaceutical Research.

[10]  G. P. Martin,et al.  Particulate Interactions in Dry Powder Formulations for Inhalation , 2000 .

[11]  G. P. Martin,et al.  The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. , 1999, International journal of pharmaceutics.

[12]  S. K. Tee,et al.  The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro , 1998 .